TCM
BBIO icon

Tang Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Tang Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-585,424
Closed -$5.82M – 93
2022
Q3 		$5.82M Buy
+585,424
New +$6.08M 0.71% 40

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tang Capital Management's BBIO Position: Q4 2022 in Review

Tang Capital Management sold out of BridgeBio Pharma (BBIO) in Q4 2022, closing a stake of 585,424 shares — an estimated $5.82M sold.

Tang Capital Management first reported a position in BBIO in Q3 2022 and held it in 1 quarter. The position peaked at $5.82M in Q3 2022. 179 funds tracked by Wall St. Rank hold BBIO as of Q4 2022.

  • Tang Capital Management reported no remaining BridgeBio Pharma position as of Q4 2022 after selling out during the quarter.
  • Tang Capital Management sold 585,424 BridgeBio Pharma shares in Q4 2022, an estimated $5.82M.
  • Tang Capital Management first reported a position in BridgeBio Pharma in Q3 2022 and held it in 1 quarter.
  • Tang Capital Management's BridgeBio Pharma position peaked at $5.82M in Q3 2022.
  • 179 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2022.

Based on Tang Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.